U.S., May 7 -- ClinicalTrials.gov registry received information related to the study (NCT07570654) titled 'Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder' on April 30.
Brief Summary: The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
PTSD - Post Traumatic Stress Disorder
PTSD
PTSD Symptoms
PTSD, Post Traumatic Stress Disorder
Intervention:
DRUG: COMP360...